Tyler Dylan-Hyde is CLO at CRISPR Therapeutics AG (CRSP). They have made 12 open-market trades across 1 company since 2017, most recently 2018-01-16.
CIK 0001674416
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CRSP | 25,204 | $1.3M |
Shares reported on the most recent Form 4, priced at the 2018-01-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CRSP | SELL | 2018-01-16 | 2018-01-18 | $28.03 | $1.9M | +38.4% | +38.1% | +76.7% |
| CRSP | SELL | 2018-01-02 | 2018-01-04 | $21.64 | $823K | +20.2% | +51.1% | +87.2% |
| CRSP | SELL | 2017-12-28 | 2018-01-02 | $22.56 | $840K | +18.3% | +59.7% | +79.5% |
| CRSP | SELL | 2017-12-22 | 2017-12-27 | $20.55 | $308K | +19.9% | +85.6% | +110.1% |
| CRSP | SELL | 2017-12-15 | 2017-12-19 | $18.90 | $284K | +32.4% | +58.2% | +171.0% |
| CRSP | SELL | 2017-08-04 | 2017-08-08 | $18.56 | $524K | -0.9% | +3.2% | +2.2% |
| CRSP | SELL · 10b5-1 | 2017-05-01 | 2017-05-03 | $16.61 | $31K | +5.2% | -12.6% | +3.7% |
| CRSP | SELL | 2017-04-28 | 2017-04-28 | $16.62 | $82K | +0.1% | -16.2% | +3.9% |
| CRSP | SELL | 2017-04-27 | 2017-04-28 | $16.84 | $228K | +0.1% | -16.2% | +3.9% |
| CRSP | SELL | 2017-04-26 | 2017-04-28 | $16.78 | $726K | +0.1% | -16.2% | +3.9% |
| CRSP | SELL | 2017-04-26 | 2017-04-28 | $16.76 | $54K | +0.1% | -16.2% | +3.9% |
| CRSP | SELL | 2017-04-21 | 2017-04-25 | $16.75 | $299K | -0.2% | -9.6% | +0.4% |
| CRSP | SELL | 2017-04-19 | 2017-04-21 | $17.59 | $317K | -4.6% | -8.5% | -2.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.